Precigen Inc Dossier - Source-backed chat

Precigen Inc

PGENNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.05

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.21Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.9B

Enterprise Value $3B

Shares Outstanding 356.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Precigen has successfully transitioned from a clinical-stage biotechnology firm to a commercial-stage biopharmaceutical company following the landmark FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) in August 2025. PAPZIMEOS is the first and only FDA-approved therapy targeting the root cause of recurrent respiratory papillomatosis (RRP) in adults. The commercial launch has demonstrated exceptional momentum, generating $21.6 million in net product revenue in Q1 2026 (its first full quarter of availability), up from $3.4 million in Q4 2025. Backed by a permanent J-code (J3404) effective April 1, 2026, and broad payer coverage extending to approximately 90% of insured US lives, Precigen is well-positioned to achieve cash flow break-even by the end of 2026. While near-term performance is highly dependent on this single asset, the underlying AdenoVerse platform is being validated, with PRGN-2009 representing a high-potential follow-on candidate in HPV-associated cancers.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$14.50

High · most bullish analyst$18.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$11.0015%

PAPZIMEOS sales growth slows down after initial pent-up demand is satisfied, or reimbursement hurdles emerge. Inovio's INO-3107 enters the market in 2027 and captures significant market share, compressing Precigen's pricing power. Slower cash conversion from accounts receivable necessitates dilutive equity financing or additional high-cost debt. WACC is modeled at 12.8% to reflect these heightened execution and competitive risks.

Base CaseCentral scenario

$14.5060%

Matches the consensus mean

PAPZIMEOS continues its steady commercial ramp in the US, supported by the permanent J-code and established patient support programs, leading to cash flow break-even by late 2026. EMA review proceeds as planned with potential approval in late 2026 or early 2027. PRGN-2009 and other pipeline assets advance steadily. Valuation is modeled using a WACC of 11.0% to 12.8% to reflect single-asset commercial dependency.

Bull CaseUpside scenario

$18.0025%

PAPZIMEOS adoption accelerates faster than expected in both major medical centers and community practices, capturing a larger share of the adult RRP market. European approval by the EMA occurs ahead of schedule in late 2026, accompanied by a lucrative ex-US commercial partnership. PRGN-2009 Phase 2 trials yield outstanding efficacy data, driving non-dilutive funding or co-development deals. WACC decreases to 10.4% as commercial execution de-risks the business model.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage with PAPZIMEOS as the first and only FDA-approved therapy for adult RRP, addressing a significant unmet medical need previously managed only by repeated surgeries.
Strong commercial launch execution, delivering $21.6 million in net product revenue in Q1 2026 and establishing a clear path to cash flow break-even by the end of 2026.
Favorable reimbursement landscape with a permanent J-code (J3404) assigned and coverage established for approximately 90% of insured US lives.
Validation of the proprietary AdenoVerse immunotherapy platform, which supports a reusable architecture for targeting other HPV-associated diseases (e.g., PRGN-2009).

Key Investment Risks

High near-term concentration risk, with overall company revenues and cash flow break-even targets heavily dependent on a single commercial product (PAPZIMEOS).
Impending competition from Inovio Pharmaceuticals' INO-3107, which is seeking accelerated approval for the same RRP indication.
Liquidity and cash burn risks if the conversion of accounts receivable (totaling $25.7 million as of March 31, 2026) is delayed or if commercial expenses exceed forecasts.
Regulatory and reimbursement risks in international markets, particularly in Europe where payers may demand lower pricing for orphan indications.

Thesis Invalidation Triggers

A sharp deceleration in PAPZIMEOS sequential revenue growth in Q2 or Q3 2026, indicating that initial sales were primarily driven by temporary pent-up demand.
Failure to achieve cash flow break-even by the end of 2026, resulting in significant equity dilution or restrictive debt covenants.
Unexpected safety signals or adverse events emerging from real-world use or ongoing redosing studies of PAPZIMEOS.
An unfavorable regulatory decision or major delay from the EMA regarding the Marketing Authorization Application.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.